OCGN - Ocugen, Inc. Short-Term Debt to Capital

This chart of Ocugen, Inc. (OCGN) asset value demonstrates metrics where the indicator is 0.00. The business relies on external contractors for testing and drug packaging, as it lacks its own facilities. Financial stability is limited due to the risk of funding shortages and the necessity of issuing new shares. The priority remains the development of antiviral agents and methods for curing vision loss.

Ocugen, Inc. (OCGN) is diversifying its portfolio through the development of gene therapies and vaccines, which requires significant operating expenses. Funding such programs makes the company sensitive to the volume of its current liabilities. This ratio measures the proportion of short-term loans relative to equity, determining the business's ability to settle debts within one year. Analyzing the trend of short-term liabilities to equity reveals critical load peaks, warning investors of liquidity risks.